Skip Navigation

JNCI Journal of the National Cancer Institute 2009 101(16):1101; doi:10.1093/jnci/djp267
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

In this Issue

The first 10% of the full text of this article appears below.

Improving the Biomarker Pipeline for Cancer Screening Tests

The development and evaluation of new biomarkers for cancer screening tests includes three stages: identification of promising biomarkers for the early detection of cancer, initial evaluation of biomarkers for cancer screening, and definitive evaluation of biomarkers for cancer screening. In a commentary, Baker (p. 1116) discusses statistical and biological issues that should be taken into account to improve this biomarker pipeline. He describes previous recommendations, including identifying cases based on clinical symptoms, keeping biomarker tests simple, and adjusting for postscreening noise. He also makes new recommendations; these include more frequent specimen collection . . . [Full Text of this Article]

Risk of HPV-Associated Cancers Among Persons with AIDS

Long-term Outcomes in Survivors of Neuroblastoma

MEK4, Genistein, and Invasion of Human Prostate Cancer Cells


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Improving the Biomarker Pipeline to Develop and Evaluate Cancer Screening Tests
Stuart G. Baker
J Natl Cancer Inst 2009 101: 1116-1119. [Abstract] [Full Text] [PDF]

Risk of Human Papillomavirus–Associated Cancers Among Persons With AIDS
Anil K. Chaturvedi, Margaret M. Madeleine, Robert J. Biggar, and Eric A. Engels
J Natl Cancer Inst 2009 101: 1120-1130. [Abstract] [Full Text] [PDF]

MEK4 Function, Genistein Treatment, and Invasion of Human Prostate Cancer Cells
Li Xu, Yongzeng Ding, William J. Catalona, Ximing J. Yang, Wayne F. Anderson, Borko Jovanovic, Kenji Wellman, Jaqueline Killmer, Xiaoke Huang, Karl A. Scheidt, R. Bruce Montgomery, and Raymond C. Bergan
J Natl Cancer Inst 2009 101: 1141-1155. [Abstract] [Full Text] [PDF]

Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
Caroline Laverdière, Qi Liu, Yutaka Yasui, Paul C. Nathan, James G. Gurney, Marilyn Stovall, Lisa R. Diller, Nai-Kong Cheung, Suzanne Wolden, Leslie L. Robison, and Charles A. Sklar
J Natl Cancer Inst 2009 101: 1131-1140. [Abstract] [Full Text] [PDF]

Does HIV/AIDS Have a Biological Impact on the Risk of Human Papillomavirus–Related Cancers?
Howard D. Strickler
J Natl Cancer Inst 2009 101: 1103-1105. [Extract] [Full Text] [PDF]

The Legacy of Cancer Therapy in Children
Elizabeth Fox, Deborah Citrin, and Frank M. Balis
J Natl Cancer Inst 2009 101: 1105-1107. [Extract] [Full Text] [PDF]